StockIQpro
NASDAQ:IMDX

Insight Molecular Diagnostics Inc.

Track all markets on TradingView
Track all markets on TradingView

Insight Molecular Diagnostics Inc.'s revenue grew 115.6% in fiscal 2025 to $4.1M while operating margin rose to −1260.8%, its highest in 6 years. Free cash flow was −$25.4M, −625.6% of revenue, and the diluted share count rose 133.2%.Summary generated from Insight Molecular Diagnostics Inc.'s SEC filings. Latest annual report filed Mar 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$4.1M
Revenue growth+115.6%
Revenue, 5-yr CAGR+27.2%
Gross margin56.7%
Operating margin−1260.8%
Net margin−1238.5%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$25.4M
FCF margin−625.6%
Share count change+133.2%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue21224
Operating income−54−18−25−61−51
Net income−64−73−28−61−50
Free cash flow−38−50−24−21−25

Recent filings

From SEC EDGAR

Peers

In vitro & in vivo diagnostic substances